• United Therapeutics recently announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to miroliverELAP, its investigational external liver assist device developed by Miromatrix to provide temporary support for acute liver failure patients using a bioengineered liver derived from decellularized porcine scaffolds and human donor cells.
• This RMAT designation, combined with earlier positive Phase 1 data for miroliverELAP and progress across United Therapeutics’ broader organ manufacturing platforms, underlines the company’s push to address the shortage of transplantable organs through bioengineered alternatives.
• We’ll now examine how the FDA’s RMAT designation for miroliverELAP could influence United Therapeutics’ long-term investment narrative and risk profile.

We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

United Therapeutics Investment Narrative Recap

To own United Therapeutics, you need to believe its pulmonary franchise can keep funding a long-term bet on complex organ and regenerative platforms. In the near term, the Tyvaso IPF label push remains the key catalyst, while trial and regulatory outcomes for ralinepag and organ programs are major swing factors. The new RMAT status for miroliverELAP is encouraging for the organ thesis, but it does not change those near term drivers or core competitive risks.

Among recent developments, the most directly relevant to miroliverELAP is the FDA clearance of the UKidney xenotransplant IND, which uses a different approach to tackle organ scarcity. Together with RMAT for miroliverELAP, it shows United Therapeutics building multiple technical paths toward organ replacement, backed by solid cash generation and active buybacks. For investors, these programs deepen the optionality around long horizon catalysts, but they also increase exposure to complex clinical and regulatory hurdles.

Yet beneath the excitement around RMAT and organ technologies, investors should be aware that United Therapeutics remains heavily exposed to a small set of core drugs and...

United Therapeutics' narrative projects $4.4 billion revenue and $1.8 billion earnings by 2029. This requires 11.1% yearly revenue growth and a roughly $0.5 billion earnings increase from $1.3 billion today.

Uncover how United Therapeutics' forecasts yield a $644.08 fair value, a 12% upside to its current price.

Exploring Other Perspectives

While RMAT for miroliverELAP strengthens the long term organ story, the most cautious analysts still assumed only about 1.8 percent annual revenue growth and flat US$1.3 billion earnings, so you should recognize how sharply views can differ before deciding which narrative feels more realistic.

Explore 5 other fair value estimates on United Therapeutics - why the stock might be worth 18% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your United Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free United Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.